Background: Case and single center reports have documented the feasibility and suggested the effectiveness of endovascular aneurysm repair (EVAR) of ruptured abdominal aortic aneurysms (RAAAs), but the role and value of such treatment remain controversial. Objective: To clarify these we examined a collected experience with use of EVAR for RAAA treatment from 49 centers. Methods: Data were obtained by questionnaires from these centers, updated from 13 centers committed to EVAR treatment whenever possible and included treatment details from a single center and information on 1037 patients treated by EVAR and 763 patients treated by open repair (OR). Results: Overall 30-day mortality after EVAR in 1037 patients was 21.2%. Centers performing EVAR for RAAAs whenever possible did so in 28% to 79% (mean 49.1%) of their patients, had a 30-day mortality of 19.7% (range: 0%-32%) for 680 EVAR patients and 36.3% (range: 8%-53%) for 763 OR patients (P Ͻ 0.0001). Supraceliac aortic balloon control was obtained in 19.1% Ϯ 12.0% (ϮSD) of 680 EVAR patients. Abdominal compartment
syndrome was treated by some form of decompression in 12.2% Ϯ 8.3% (ϮSD) of these EVAR patients. Conclusion: These results indicate that EVAR has a lower procedural mortality at 30 days than OR in at least some patients and that EVAR is better than OR for treating RAAA patients provided they have favorable anatomy; adequate skills, facilities, and protocols are available; and optimal strategies, techniques, and adjuncts are employed.
(Ann Surg 2009;250: 818 -824) E ndovascular repair of a ruptured abdominal aortic aneurysm (RAAA) was first performed successfully by Marin, Veith et al on April 21, 1994 . 1 Another case was first reported by Yusuf, Hopkinson et al in 1994. 2 Since then many centers have employed endovascular aneurysm repair (EVAR) to treat RAAAs with varying results. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Several groups have developed standardized systems of management in the RAAA setting, have used EVAR whenever possible and have achieved good results with EVAR. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In contrast other authors have used EVAR for RAAAs more selectively and have reported no better results with EVAR than with traditional open repair. 14 -16 The purpose of the present study was to collect a large sample of the world experience with EVAR for RAAAs and to use this along with that of a single center to explain or reconcile the variable results that have been achieved with this form of treatment. Because management strategies and technical factors may in part account for these variable results, we will examine approaches and results in those centers with better results and highlight those strategies, adjuncts and techniques which appear to be crucial in obtaining better treatment outcomes.
METHODS
Only documented ruptured abdominal aortic or aortoiliac aneurysms were considered in this study. Rupture was defined as the clear presence of blood outside the aortic wall on preprocedural or postprocedural computerized tomographic (CT) scans or at laparotomy.
Questionnaires were sent to physicians or centers that had published articles on the use of EVAR for RAAAs or were known to have performed this form of treatment. The original questionnaires were sent out between July 1, 2002 and December 1, 2006 and returned by December 31, 2007.
Center Information
Center Information was requested by questionnaire on the total number of RAAAs treated by EVAR and open repair (OR); the number of deaths within 30 days in each group; the criteria for performing EVAR (anatomic suitability, hemodynamic stability, staff availability, or operator preference); the requirement for a preprocedural CT scan (with or without contrast); and the location where EVAR was performed (operating room or angiography suite). Information was also requested on whether or not a protocol or standardized system was used, which endograft was inserted, whether or not a supraceliac balloon was placed, the criteria and technique for its use, the type of anesthesia, whether or not fluid resuscitation was restricted (hypotensive hemostasis), whether or not abdominal compartment syndrome (ACS) was searched for and how it was detected and treated. We also examined publications describing each centers' method and results for treating RAAAs.
Individual Patient Information
A second questionnaire form was requested for each RAAA patient treated by EVAR. This form requested information on the date of EVAR, the endograft used, whether or not a preprocedural CT scan was obtained, the occurrence of hypotension with a systolic arterial pressure Ͻ70 mm Hg (hemodynamic instability), the occurrence of arterial pressure Ͻ50 mm Hg (profound hemodynamic instability), or circulatory collapse with a systolic arterial pressure Ͻ40 mm Hg. Further information was requested on use of a supraceliac balloon, whether the rupture was deemed to be contained, the type(s) of anesthesia used, and whether ACS was treated by laparotomy and hematoma evacuation or open decompression (open abdomen treatment). Information about complications and the duration of survival was also requested.
Completed questionnaires were received from 49 centers ( Table 1-3) . Although the center and patient information received was not always complete, the EVAR 30-day mortality data were. For parameters in which the data were incomplete, some descriptive generalizations or calculations of relative proportions for centers and cases could be made, as with preprocedural CT, local anesthesia, endograft type and configuration, and balloon usage. With other variables, incomplete data precluded accurate analysis.
Updated Questionnaire
To reflect best the current state of the art of EVAR for RAAA treatment an updated questionnaire was sent on December 15, 2008 to 15 centers which employed EVAR to treat all or almost all anatomically suitable RAAAs. Of these 15 centers, 13 responded. These 13 were also generally the ones which had developed a standardized management protocol for RAAAs, had the largest series of cases treated with EVAR and had the most favorable outcomes. Even when standardized management systems were de- veloped, they were not used universally or during centers' early experience.
The experience of a single center (Montefiore Medical Center in New York), in which EVAR was used to treat almost all anatomically suitable RAAAs over 14 years, was analyzed to show one system of management. Improvements in this system, based on advances developed in other major centers, are highlighted herein to optimize the management of RAAAs by EVAR and OR.
RESULTS
Responses to questionnaires were received from 49 centers which had used EVAR for RAAAs. Forty-six centers responded to the initial questionnaire, and 3 additional centers as well as 10 initial centers responded to the updated questionnaire. As shown in Tables 1, 2, and 3, the centers responding to the initial questionnaire were divided into 3 groups depending on the number of RAAA patients treated by EVAR. Those centers with the largest number of patients (24 -62) are shown in Table 1 . In these centers 30-day overall mortality for the 524 patients was 21.0% with a range of 7% to 39% and a mean center mortality of 21.8 Ϯ 10.4 (SD) %. Survival and mortality data for the centers using EVAR for the treatment of 11 to 18 RAAA patients are shown in Table 2 . Mortality within 30-days for this group of 111 patients was 22.5% with a range of 6% to 43%. Table 3 details mortality data for centers performing EVAR on 5 to 10 RAAA patients, a total of 54 patients with a 30-day mortality of 30%, and for centers performing EVAR on 1 to 4 RAAA patients, a total of 37 patients with a 30-day mortality of 35%. Table 3 also shows the overall 30-day mortality for all 726 patients reported to undergo EVAR for a RAAA in response to the original questionnaire. In this entire group of patients, the 30-day mortality was 22.6%. When the outcomes for the additional 311 patients reported in response to the updated questionnaire were included, the overall 30-day EVAR mortality for the 1037 EVAR patients was 21.2%.
The data reported on patient and procedural details were incomplete for some of the 1037 patients. Nevertheless the responses to the initial questionnaires showed that several aspects of care in the 46 original centers varied greatly. These variables and generalizations about them include the following:
Endografts Used. The type of endograft used was reported in 327 patients. These grafts are detailed in Table 4 . Most of the grafts (82%) were modular; 18% were unibody. Of the 327 grafts reported, 43 or 13% were fabricated by surgeons. The rest were industry-made or used industry made components.
Indications and Contraindications for EVAR. Although some centers attempted to use EVAR to treat all RAAAs with suitable neck and iliac artery anatomy, they were occasionally prevented from doing so by staff and graft unavailability. Other centers treated only patients who were hemodynamically stable, although how that was defined varied widely. In some centers, systolic blood pressure (BP) Ͻ90 or Ͻ80 mm Hg constituted instability. In others any BP Ͻ70 mm Hg equaled instability; in others, this level of BP had to be sustained. In still others, instability equaled a BP Ͻ50 mm Hg. Moreover, some centers used EVAR only on patients whose BP never fell below 90 mm Hg and/or who had contained ruptures, although the criteria for defining this varied. Resuscitation. There was variability in how RAAA patients were resuscitated. Many centers infused fluids to keep the systolic BP at a certain level. Others aggressively restricted resuscitation (Hypotensive Hemostasis) in an effort to decrease bleeding and its detrimental consequences. 4,5,17 Preprocedural CT Scans. There was variability in the rapid availability and use of preprocedural CT scans. If time and transport of the patient to another institutional locale was involved, a CT scan was more likely to be omitted. If rapid CT was available in the emergency room, it was more likely to be obtained. Most centers would only perform EVAR after a CT scan was obtained. Three centers routinely avoided CT scans in their unstable patients with a presumptive diagnosis of a RAAA. If the diagnosis was clear, patients were taken directly to the operating room where the decision to perform EVAR or OR and all necessary endograft measurements were based on intraoperative contrast cine fluoroscopy. 4, 18 In these centers, CT scans were obtained on stable patients or if the diagnosis was in doubt. Staff Availability. In some centers, staff availability and skills were a major determinant of whether a RAAA patient would be treated by EVAR or OR. Anesthesia. General, epidural, or local anesthesia with sedation 3 were all used successfully in various centers. Some centers used a combination. Supraceliac Aortic Balloon Control. This was used in some but not all centers performing EVAR in unstable patients. However, the indications and techniques for use varied widely. Some centers used it only when there was complete cardiovascular collapse with a BP Ͻ40 mm Hg. Others used it on all unstable patients, and still others on profoundly unstable patients (BP Ͻ50 mm Hg). The proportion of patients in which an aortic balloon was used varied from 0% to 48%, but ranged from 18% to 23% in most larger series. Abdominal Compartment Syndrome. The diligence with which this was searched for after EVAR, its incidence and the aggressiveness of treatment varied widely. Some routinely measured bladder pressure and opened the abdomen in the absence of organ failure. 5, 13 Others only did so when the BP, lung and renal function deteriorated. 4, 7 Different techniques were also employed in dealing with the open abdomen after decompression was performed. 19 Complications. Although these were not reported systematically, 2 EVAR treated patients required laparotomy for hypotension and were noted to be bleeding from a Type II endoleak. Despite suture control of the bleeding, both patients died. EVAR in hemodynamically unstable and otherwise high risk patients, the 30-day mortality after 680 EVARs in these centers was 19.7%. The mean mortality among centers was 17.4% Ϯ 8.9% (ϮSD) with a range of 0% to 32%. OR was used to treat 763 or 53.3% of all the RAAA patients undergoing treatment at 12 of 13 of these centers (Atlanta OR data not included). The 30-day mortality for OR was 36.3% with a range of 8% to 49% and a mean among centers of 35.8% Ϯ 12.4% (P Ͻ 0.0001 for EVAR vs. OR by 2 analysis). Table 5 also shows that the percentage of RAAA patients that were treated by EVAR ranged in 12 of the 13 centers from 28% to 79% with a mean of 49.1% Ϯ 12.9% (ϮSD). The proportion of EVAR treated patients in whom aortic balloon control was employed averaged 19.1% Ϯ 12.0% (ϮSD) in the 13 centers with a range from 2% to 48%. The proportion of EVAR treated patients in whom ACS was recognized and treated by laparotomy, hematoma evacuation or open abdomen techniques in the 13 centers averaged 12.2% Ϯ 8.3% (ϮSD) with a range of 2% to 29%.
Updated Questionnaire Results

Single Center Experience
Between April 22, 1994 and January 15, 2008, 57 patients with RAAAs were treated at Montefiore Medical Center in New York. Much of this experience has been described in previous publications. 4, 18 In brief, after an initial EVAR experience (17% 30-day mortality) in 12 RAAA patients who were deemed unsuitable for OR, the policy was to use EVAR on all patients who were anatomically suitable if appropriate staffing and endografts were available. 4 A total of 45 patients were treated with endografts and 12 with OR. In the EVAR patients 25 received surgeon-made endografts and 20 received industry made modular endografts. When a surgeon-made endograft was used, it was constructed of a large balloon expandable stent and a tulip shaped PTFE graft placed in an aortouni-femoral position with contralateral iliac artery occlusion and a femorofemoral bypass. 4 Of the 57 RAAA patients, 10 underwent OR because of unsuitable anatomy for EVAR, whereas 2 had OR because of staff or graft unavailability. Many patients treated by EVAR were prohibitive risks for open repair, yet many of these survived (Fig. 1) .
EVAR was performed without a preprocedural CT scan in 17 RAAA patients. In these patients suitability for EVAR and graft sizing measurements were made from intraoperative arteriography, using calibrated catheters. In the other 28 patients, a preprocedural CT scan was obtained because of uncertainty in the diagnosis or because the patient was initially admitted to another hospital or service. No differences in outcomes were observed between these 2 small groups.
Fluids were aggressively restricted and the patient's BP was allowed to fall without fluid administration to 50 mm Hg or less if the patient was moving or talking. 4 Although local anesthesia was used in the early phases of most EVAR procedures (placement of catheters, guidewires and sheaths), general anesthesia was used to prevent motion to improve imaging and allow precise endograft deployment. Large sheath placement and balloon occlusion was only used if patients had cardiovascular collapse. This was only required in 10 of 45 patients undergoing EVAR and 3 of 10 undergoing OR. The technique for continuous balloon control of the aorta while deploying a modular endograft has been described. 20 ACS was detected in only 3 of the 45 EVAR patients when they became hypotensive and difficult to ventilate. Laparotomy and evacuation of the hematoma relieved the problem. However unrecognized ACS 
DISCUSSION
EVAR has been used increasingly to treat patients with RAAAs and offers many theoretical advantages over OR. It is less invasive, eliminates damage to periaortic and abdominal structures, decreases bleeding from surgical dissection, minimizes hypothermia, and lessens the requirement for deep anesthesia. Because of these potential advantages and reports of lower procedural mortality, EVAR has been deemed superior to OR for the treatment of RAAAs. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, other groups have been unable to confirm this superiority, so the role of EVAR remains controversial. 14 -16 Our collected experience with the use of EVAR to treat 1037 patients with a RAAA or a ruptured aortoiliac aneurysm show an overall 30-day mortality of 21.2%. This 30-day mortality is clearly less than that of OR for RAAAs as reported in multiple studies which ranges from 35% to 55%. [22] [23] [24] However, in the collected experience many of the centers limited the use of EVAR to "stable" RAAA patients or even those with "contained" ruptures. Because hemodynamic instability is associated with a higher risk of procedural mortality, 5, 8, [22] [23] [24] it is totally invalid to compare the lower procedural EVAR mortality rates with those for OR. Additional potential flaws in the overall data from this collected experience study are lack of systematic mid-and long-term follow-up, possible inaccuracies in the reporting, some incompleteness of the reported data, changes or improvements in strategies and techniques with time and experience, the occurrence of some procedural deaths after 30 days, the possibility of missed centers and cases, and the fact that many of the reporting centers included only their limited early experience in Tables 1, 2, and 3 .
For these reasons we examined updated outcomes for EVAR in a selected group of 13 centers that were committed to performing EVAR to treat all RAAA patients who were anatomically suitable for endograft treatment, including those that were hemodynamically unstable and those in profound shock. These centers were usually the ones with the larger experience ( Table 5 ). Although there was some variability in the approach of these centers to the treatment of RAAA patients, most had some degree of standardization and many had a defined protocol. 5, 8, [11] [12] [13] All were experienced in the use of EVAR and endovascular adjuncts for elective abdominal aneurysm treatment and all had dedicated endovascular facilities and imaging equipment. Despite the use of EVAR to treat almost all anatomically suitable RAAA patients, the 30-day mortality for EVAR was a favorable 19.7% with a range of 0% to 32% (Table 5 ). One outlier in the group (Modena) excluded from EVAR patients Ͻ65 years of age, thereby biasing the EVAR treatment results with higher risk elderly patients. A second outlier (Malmo) may have biased the EVAR treatment group by including some higher risk juxtarenal aneurysm patients, and 61% of this center's EVAR patients were unstable with a BP Ͻ70 mm Hg. In addition, the wide variability in 30-day EVAR mortality in Table 5 may reflect differences in patient mixes and risk stratification as well as treatment details in the various centers.
Nevertheless, these updated outcome results from centers committed to EVAR treatment of all possible RAAAs (Table 5) suggest that EVAR is a superior way to treat RAAAs ͓overall 30-day mortality of 19.7% for EVAR vs. 36.3% for OR (P Ͻ 0.0001)͔. However, the validity of this comparison is limited because the cases of RAAA were still not comparable in the 2 groups. More anatomically difficult patients were subjected to OR, and they may have also had more high risk factors. Nevertheless, this updated collective experience indicates that EVAR is a better way to treat RAAAs in those patients who have aortic neck and iliac anatomy suitable for the procedure. It also indicates that those who care for RAAA patients must be able to perform OR and other surgical procedures as well as EVAR, as EVAR in these patients may also require some adjunctive open component such as femorofemoral bypass, an iliac conduit or laparotomy, and hematoma evacuation.
Additional proof that EVAR is a better treatment for some RAAA patients is that many patients in this collected experience Open repair was advised but the patient refused blood transfusion. The hematocrit fell from 27% to 17%, the systolic arterial blood pressure decreased from 90 to 60 mm Hg and the patient became confused. Open repair was thought to carry a prohibitive risk. C, Arteriogram showing a short angulated aortic neck. Note left renal artery appearing to arise from the aneurysm. An AneuRx endograft is in place but not yet deployed. D, Contrast CT scan 6 weeks after the procedure. The aneurysm is excluded. The left renal artery is perfused. The patient remains well over 5 years later. who were categorically unsuitable or prohibitively high risk for OR survived for many years after EVAR. Figure 1 shows an example of such a patient.
The low EVAR procedural mortality that was achieved in the updated experience (Table 5 ), emphasizes the importance of several key strategies, adjuncts and technical factors in achieving these good results with EVAR for RAAAs.
Standard Approach or Protocol
These allow the most effective decision-making and treatment of these patients in what are often confusing and stressful circumstances. [11] [12] [13] They are also important to facilitate education in and recognition of RAAAs by generalists, emergency room personnel, and others to enable early diagnosis and mobilization of the specialized care givers best trained to optimize treatment.
Fluid Restriction (Hypotensive Hemostasis)
Fluid resuscitation should be restricted even if the patient becomes hypotensive. Experience has shown that systolic arterial pressures of 50 mm to 70 mm Hg are well tolerated for short periods and limit internal bleeding and its associated loss of platelets and clotting factors. 4, 5, 17 Whether or not pharmacological lowering of blood pressure is beneficial remains to be conclusively shown. 5, 13 Treatment Site 
Anesthesia and Catheter-Guidewire Placement
The latter should be obtained percutaneously under local anesthesia. This permits arteriography to define aortic and arterial anatomy, facilitates large sheath and supraceliac balloon placement if needed, and prevents circulatory collapse caused by the induction of general anesthesia. Whether general anesthesia is used later to eliminate motion and improve fluoroscopic imaging to permit precise graft deployment remains controversial. Some groups have successfully used local anesthesia supplemented by sedation throughout as an alternative. 3, 5, 13 
Supraceliac Aortic Sheath Placement and Balloon Control
Most groups favor their use only when there is severe circulatory collapse. In such cases, deflation of the balloon before sealing of the rupture site will result in immediate recurrence of the circulatory collapse. Therefore, techniques have been developed to maintain continuous aortic control until the endograft has sealed the leak. 3, 4, 20, 21 These techniques use multiple balloons to minimize renal and visceral ischemia by placing secondary balloons within the endograft as the supraceliac balloon is deflated and removed through its supporting sheath.
Endograft Type and Configuration
Both bifurcated and aortouni-iliac (or femoral) grafts can be used successfully, although some patients have unilateral iliac disease which mandates a unilateral configuration. Modular and unibody grafts have been used successfully in both configurations. An appropriate inventory of suitable grafts and accessories must be stocked sterile in the treatment site and be available for the procedure and unexpected contingencies.
Abdominal Compartment Syndrome
Abdominal compartment syndrome is a major cause of morbidity and mortality after EVAR for RAAA. It is advantageous to keep a high index of suspicion for this entity. Laparotomy and hematoma evacuation have alleviated the hypotension, high ventilatory compliance, and oliguria that occurs with the full blown syndrome. Monitoring bladder pressure has been helpful in the early detection of the syndrome, 5, 7, 13 and early laparotomy with open abdomen treatment and suction/sponge (VAC) dressings may decrease mortality and allow survival in otherwise hopeless circumstances when small bowel and mesenteric edema cause loss of domain for the abdominal viscera. 19 
EVAR for Worst Risk Patients
It is probable that EVAR is most beneficial in augmenting survival when it is used in the worst risk patients who are unlikely to survive an OR. Patients with hemodynamic instability and profound circulatory collapse, a hostile abdomen, or those unable to receive transfusion would fall in this category. If such patients, particularly those that are hemodynamically unstable, are excluded from EVAR, it is likely that the improved survival that can accrue from this form of treatment will be diminished. It is for this reason that the updated data presented in Table 5 were restricted to centers which use EVAR on almost all patients whose aortic neck and iliac artery anatomy was suitable for the procedure.
The reduced 30-day mortality compared with patients treated by OR (Table 5 ) together with the ability to obtain survival in many RAAA patients who were prohibitive risks for OR constitute strong evidence that EVAR is a better way to treat RAAAs in at least some patients, provided the described strategies, adjuncts and techniques are employed. Furthermore, as others have already indicated, 6,9 some of these methods will also improve survival in RAAA patients treated by OR. Hypotensive hemostasis and supraceliac balloon control for patients in circulatory collapse are 2 examples.
Finally is the question of the need for a randomized controlled comparison of EVAR and OR in RAAA patients. The data from our collected experience suggest that one is not needed. If those who believe such evidence is necessary to confirm the value of EVAR in the RAAA setting wish to perform such a trial, we await its results with interest. However, such a study will be difficult to perform, and we believe that it has been rendered unnecessary not only by this collected experience but also by the results of many single center reports.
Discussions
PROFESSOR R. GREENHALGH: What we need, manifestly, is a higher level of evidence. A randomized controlled trial is required and I would favor the design of a RCT towards CT scan wherever possible performing endovascular repair, against open repair, which, at the moment, is the gold standard the world over and is, in my view, required to shift practice beyond the enthusiasts gathered here to inform us. I take away from this study that we can expect a 15% improvement in operative mortality and your work is valuable in helping to establish the power calculations for the improved randomized controlled trial now funded to address this important topic.
My question is whether you still maintain that your enthusiasm for EVAR and emergency EVAR is so strong that a randomized controlled trial is absolutely not required? DR. FRANK J. VEITH: I believe that a randomized trial, as I have said publicly before, of endovascular versus open repair in ruptured aneurisms, for those who can get good results, is a bit like performing a randomized trial of parachutes! I do not think it is necessary. Certainly I am an enthusiast, but there are at least a dozen other equally enthusiastic centers, which have obtained results that are comparable to ours. They are all centers that have a system and that see a lot of ruptured aneurisms, which we do not see anymore, probably because of the surveillance programs. I believe that if you can conduct a randomized trial in Britain, I will applaud you and look at it with great interest. However, I also believe that it will be a very difficult trial to carry out. One of the problems is that you talk about doing CT scans. In many hospitals, it takes time to get CT scans, and we did not obtain them preoperatively in all our patients because 2 of them died while having a CT scan. Thus, I think anything you can do to shorten the time between getting the wire, the sheath and the balloon to control bleeding in the totally collapsing patient is worthwhile. Getting a CT scan first in that setting is, I believe, a mistake-at least in a center where you cannot obtain one quickly. If you have a CT scanner in the emergency room and it can be done in 10 minutes, then you should proceed with one. However, I do not believe a randomized trial is necessary for most groups. PROFESSOR H. GOOSZEN: Collecting all these data from 49 centers is an impressive amount of work, and I share your worry in performing a randomized controlled trial on this issue. Do you think your database is suitable for the second-best option, performing a case controlled study on the data you have available? DR. FRANK J. VEITH: That was the essence of our second questionnaire, but it still does not compare apples with apples; it compares apples with ripe apples. This is because the 13 centers that used EVAR on all the patients they could and used open repair on all the others because they were anatomically unsuitable for EVAR, may also have used open repair on patients who were coincidentally at higher risk. Thus, I do not believe that we can do any better than that with these data. The most convincing data came from the second questionnaire. I believe that those data plus the 10% to 15% of patients who were treated by EVAR who could never have survived open repair are as convincing as anything we can ethically ever achieve.
Everyone must also recognize that there are many limitations to a cooperative multicenter study like ours, the main one being that every center does not provide all the details of the data that we requested, making it difficult or impossible to compare outcomes from different centers. Also, there is no question that the 49 centers were a very mixed bag, and the data from them are difficult to analyze fully in a meaningful and statistically valid way. However, the data from the 13 centers in the second questionnaire were up-to-date and quite meaningful. A great deal of this information and other details were published separately as part of single center reports that we referenced in the manuscript. The Zurich group and the Albany group are particularly notable in this regard. They produced several articles that have been or will be published. These articles show how these groups developed systems and educated their referring and emergency room physicians to cut down this delay between aneurysm rupture and treatment time. They (especially the Zurich group) have popularized recognition of the Abdominal Compartment Syndrome and how to diagnose it aggressively and treat it well. I believe this is a very important advance that will help improve survival with EVAR treatment of ruptured AAAs. Also important is the way one uses the supraceliac balloon in this setting. The balloon should only be used when it is truly needed and there are many technical tricks and techniques needed to use these balloons effectively. These are described and referenced in the manuscript, along with many other treatment details (especially hypotensive hemostasis), which make a difference in the outcomes after treatment for this condition.
